**Core tip:** This mini-review summarizes recent findings of traditional serrated adenoma. The origin of traditional serrated adenoma and its molecular pathogenesis are discussed in details.

INTRODUCTION
============

Colorectal carcinoma (CRC) is a heterogeneous disease in terms of its molecular pathways of carcinogenesis. Most, if not all CRCs, arise from conventional adenomas or serrated lesions, the latter accounting for 5%-35% of CRC\[[@B1],[@B2]\]. Serrated polyps include hyperplastic polyps (HPs), sessile serrated lesions (SSLs), traditional serrated adenomas (TSAs) and unclassified serrated adenomas according to 2019 World Health Organization classification of colonic epithelial neoplasms\[[@B3]\]. Sessile serrated lesions and TSAs are regarded as precursors to CRC, while small HPs are considered to have little risk for neoplastic progression. TSAs comprise 0.56%-1.9% of colorectal polyps and are the least characterized serrated lesions in the colorectal carcinogenesis\[[@B4]-[@B6]\]. Endoscopically, TSAs show exophytic protuberant configuration and pinecone-like appearance\[[@B7],[@B8]\]. Histologically, TSAs feature architectures of complex filiform or villiform growth pattern, slit-like or flat-top serration and ectopic crypt formation (ECF) which is defined as small rudimental crypts located on the side of villous structure and displaced from bottom muscularis mucosa. Cytologically, TSA is characterized by lining of epithelium with abundant eosinophilic cytoplasm, pseudostratified pencillate nuclei and dispersed chromatin (Figure [1](#F1){ref-type="fig"})\[[@B9]\]. Although it is debatable which feature is the most sensitive and which one is the most specific, it is agreed that none of them alone is sufficient or required for diagnosing TSA. Fulfilling 2 out of 3 core features (ECF, eosinophilic cytoplasm and slit-like serration) may be more reproducible in making the diagnosis of TSA\[[@B10]\].

![Low and high power view of the traditional serrated adenoma. A: A low power view (40×) of the traditional serrated adenoma shows viliform growth of the polyp with slit-like serration; B: A high power view (100×) demonstrates ectopic crypt formation, eosinophilic cytoplasm and pencillate nuclei.](WJGP-11-78-g001){#F1}

The molecular pathogenesis of TSA is poorly understood due to its rarity. Less is known about the mechanism that drives precursor lesions and their subsequent risk of progression. In this review, we will present the currently available literature, focusing on the origin of TSA. We will also attempt to correlate the molecular changes with morphologic features, which might help us understand how TSAs develop from precursor lesions or *de novo*.

ORIGIN OF TSA
=============

TSAs are probably underdiagnosed by pathologists for several reasons. TSAs are the rarest among the three serrated colonic polyps, comprising of about 5% serrated polyps and 0.56%-1.9% of all colorectal polyps\[[@B4]-[@B6]\], and widely accepted consensus criteria for diagnosing TSA were not available until recently. Chetty\[[@B11]\] listed a constellation of architectural and cytological features of TSA in a succinct review of the entity. However, none of these features are unique or specific for TSA. The minimal criteria for diagnosing TSA are also not specified in many studies. Additionally, TSAs are often admixed with HP or SSL\[[@B8],[@B12],[@B13]\], causing difficulty in recognition. Three variants of TSA were described, the prototypical filiform TSA, the less common flat TSA\[[@B12]\] and the rare mucin-rich TSA\[[@B9]\].

Genetic heterogeneity of TSAs contributes to the variation in cytomorphology. Almost 90% of TSAs develop through two mutually exclusive pathways: *BRAF* mutation (56.4%) and *KRAS* mutation (31.9%)\[[@B8],[@B12]-[@B15]\] (Table [1](#T1){ref-type="table"}). The remaining 10% may have other pathways involved such as EGFR (Figure [2](#F2){ref-type="fig"})\[[@B16]\] that appears to segregate with *KRAS*-mutated polyps\[[@B12]\]. *BRAF* gene encodes an anti-apoptotic serine-threonine kinase. *BRAF* V600E activating mutation is an early event that drives serrated lesion into CRC\[[@B17],[@B18]\]. TSAs with *BRAF* mutation often show a flat growth pattern with serrated dysplasia, high CpG island methylator phenotype (CIMP) and are more likely located in the proximal colon than *KRAS*-mutated TSA\[[@B8],[@B12]\]. *KRAS*-mutated TSA are usually distally located and exophytic with adenomatous dysplasia. In addition to *KRAS* mutation, TSAs from distal colon show selective methylation of *SMOC1* gene and loss of its expression, which are also frequently associated with high-grade adenoma and CIMP-low/microsatellite stable CRC\[[@B19]\].

###### 

Histologic and molecular changes in traditional serrated adenoma

  **Country/Territory**   **Polyp**   **Distal**    ***BRAF***    ***KRAS***   **Wild type**   **ECF**         **Slit-like serration**   **Typical cytology**   **Ref**.
  ----------------------- ----------- ------------- ------------- ------------ --------------- --------------- ------------------------- ---------------------- ------------
  United States           24          96% (23)      29% (7)       46% (11)     25% (6)         NA              NA                        79% (19)               \[[@B14]\]
  South Korea             107         74.8% (80)    55.1% (59)    33.6% (36)   11.2% (12)      79.4% (85)      100% (107)                100% (107)             \[[@B8]\]
  Taiwan                  60          61.7% (37)    35% (21)      52% ( 31)    13.3% (8)       NA              NA                        NA                     \[[@B13]\]
  Australia               200         71% (142)     67% (134)     22% (43)     11% (23)        89% (178)       98% (196)                 100% (200)             \[[@B12]\]
  Japan                   129         82.2% (106)   61.2% (79)    34.8% (45)   3.9% (5)        NA              NA                        NA                     \[[@B15]\]
  Australia               70          71% (50)      47% (33)      31% (22)     21% (15)        67% (47)        81% (57)                  NA                     \[[@B20]\]
  Total                   590         74.2% (438)   56.4% (333)   31.9%(188)   11.7% (69)      82% (310/377)   95% (360/377)             98.5% (326/331)        

Numbers in parenthesis are case numbers. ECF: Ectopic crypt formation; NA: Not applicable.

![Histologic changes of traditional serrated adenoma parallel molecular alterations. During traditional serrated adenoma (TSA) development, mutations in *BRAF* (*BRAF*^mut^), *KRAS* and *EGFR* cause typical cytomorphology and serration in precursor lesions. Accumulation of molecular alterations such as aberrant WNT signaling leads to fully developed TSA. Other pathways (Bone morphogenetic protein?) in addition to WNT signaling might also be involved in this step. Finally, mutations such as *TP53* will cause the progression of TSA into high-grade dysplasia and malignant transformation.](WJGP-11-78-g002){#F2}

TSAs may arise from precursor lesions of microvesicular HP or SSL or may occur *de novo*. *BRAF* mutated TSAs are also more likely admixed or associated with HP or SSL-like lesions, which are identified in TSA in 38%-52.3% of cases\[[@B8],[@B12],[@B20]\]. One early study suggested that serrated precursor lesions adjacent to distal TSA are distinguished from SSL by lack of Annexin A10 despite shared morphologic and molecular features\[[@B21]\]. Annexin A10 is normally expressed in upper gastrointestinal tract\[[@B22]\]. It is identified as a marker of SSL\[[@B23]\] and is expressed in colorectal cancer of serrated pathway undergoing gastric programming\[[@B24]\]. Thus, it is not surprising that the serrated precursor lesions of TSA in this study, arising predominantly from distal colon, are distinctive from proximal colonic SSL\[[@B21]\]. It is more likely that small flat TSAs identified in proximal colon would be expressing Annexin A10. More recently, Bettington and colleagues compared small polyps (\< 1 cm) (71% from the distal colon) and shoulder lesion in large TSAs, demonstrating similar immunophenotypic and molecular profiles\[[@B20]\]. These findings support that small TSAs do exist and may arise at least partially from some HP/SSL-like precursors.

WNT signaling is the main driver of colon cancer and physiological proliferation of colonic crypts\[[@B25]\]. Alterations in components of WNT pathway including mutations of *RNF43*, *APC* and *CTNNB1*, and overexpression of *RSPO* (due to fusion gene or amplification), can all lead to stabilization and nuclear localization of β-catenin and activation of WNT signaling\[[@B26]\]. Nuclear β-catenin staining, as well as p53 positivity, loss of p16 and *MLH1* promoter methylation is seen in the late development of polyps with dysplastic features\[[@B12],[@B13]\]. However some molecular studies showed that components of WNT signaling are frequently altered in TSAs (30%-70%) regardless of the degree of dysplasia\[[@B15],[@B27]\]. A recent study using microdissection to interrogate genetic changes revealed a stepwise molecular change in TSAs and associated precursors\[[@B28]\]. Clonally, the HP/SSL-like precursors share the identical mitogen-activated protein kinase (MAPK) pathway gene mutations (*BRAF* or *KRAS*) with TSAs. However, these precursors exhibit fewer mutated *WNT* pathway genes or heterozygotic mutations (*i.e*., *RNF43*, *APC*, and *CTNNB1*) than TSA with biallelic inactivation. This study supports the sequence of MAPK to WNT alterations in TSA developing from HP and SSL-like lesions (Figure [2](#F2){ref-type="fig"}). One drawback of this study is that only one out of 15 polyps had *KRAS* mutation. Hence TSAs with *KRAS* mutation, which are predominantly found in the distal colon and typically are large in size, remain of uncertain in terms of origin and critical molecular alterations during development.

HISTOLOGIC-MOLECULAR CORRELATIONS
=================================

The presence of histologic features in TSAs is highly variable depending on their size and location. ECF is considered relatively more specific whereas slit-like serration and typical cytology are more sensitive features (Table [1](#T1){ref-type="table"}). Serration is the common feature of HP, SSL and TSA. However, the cytomorphology of these three entities differs, reflecting distinct mechanisms underlying their development. *BRAF* or *KRAS* are two initiating mutations commonly seen in serrated polyps, activating MAPK pathway. HPs are characterized by saw-toothed serration in the upper half to third of the crypts and absence of basal crypt dilation\[[@B29],[@B30]\]. Epithelial proliferation with defective apoptosis\[[@B5]\], delayed crypt cellular migration and maturation toward the surface leads to infolding of epithelial lining and formation of HPs. The majority of HPs are innocuous, largely because *KRAS* mutation in HP does not expand the stem cell pool but instead increases transit-amplifying cells in the mid and upper regions of crypts\[[@B31]\].

By contrast, SSLs have irregular proliferative zones and bidirectional maturation toward both surface and base of the crypt, causing pathognomonic basal crypt dilation and lateral spread of crypt base\[[@B32]\]. This architectural change was suggested to be similar to gastric foveolar growth pattern characterized by a mid-level proliferative compartment and bidirectional differentiation\[[@B11]\]. Another salient feature of SSLs is prominent inhibition of apoptosis in contrast to HPs and TSAs\[[@B33]\].

Compared to HP and SSL, TSAs have slit-like, flat-top serration rather than saw-toothed serration. Eosinophilic cells in TSA with luminal brush border and a prominent villiform growth pattern are the features reminiscent of small intestine morphology\[[@B9]\]. It was believed that eosinophilic cytoplasm seen in TSA is due to cellular senescence\[[@B32]\]. Senescence and apoptosis are two protecting approaches of cells and tissue in response to oncogenic stresses\[[@B34]\]. They are the barriers that must be overcome in precursor lesions to promote and progress into fully developed TSAs. In TSAs, depending on locations, *BRAF* or *KRAS* are the initiating mutations activating MAPK pathway. Both, however, may cause cellular senescence and cell cycle arrest through p53/p21 axis or p16INK4 activation\[[@B29],[@B34]\]. SSL is also well known to have high rate of *BRAF* mutation\[[@B18]\]. Therefore, it is not uncommon to observe occasional eosinophilic atypical cells in SSLs\[[@B32]\]. Animal models supported that *BRAF* V600E mutation causes cellular senescence after first wave of proliferation\[[@B35]\] and a shift of balance from proliferation to differentiation, which can be rescued by a loss of additional differentiation-promoting factors (CDX2, SMAD4 and p16) or activation of WNT signaling\[[@B36]\]. In SSLs and TSAs located in proximal colon, hypermethylation of *P16INK4* promoter and loss of p16 expression are the late events\[[@B12]\] that may cause evasion of senescence program implemented by *BRAF* mutation, whereas activation of WNT is likely the pathway employed for the progression of distally located TSAs.

ECF is a key feature of TSAs, especially in large protuberant ones in the distal colon. The presence of ECF in TSAs ranges from 67% to 89%, depending on the location and size of the polyps\[[@B8],[@B12],[@B20]\]. ECF is defined as small crypts displaced from muscularis mucosa, likely representing a progression step by disrupting the signalings of colonic crypt homeostasis. Bone morphogenetic protein (BMP4) signaling is probably a good candidate. BMP signaling plays an important role in villus morphogenesis and is known to promote cell differentiation and repress crypt formation\[[@B37],[@B38]\]. Studies using human pluripotent stem cells demonstrated that BMP signaling is only transiently required for colonic differentiation, while small intestinal differentiation is the default program in the absence of BMP signaling\[[@B10]\]. Loss of BMP signaling in animal model\[[@B37]\] leads to ectopic crypt foci that resembles the phenotype of juvenile polyposis syndrome, which is known to harbor *BMPR1A* and *SMAD4* mutations in human\[[@B39],[@B40]\]. Therefore, it is possible that ECF and villiform growth of TSA represent dysplastic transformation of colonic crypts into small intestinal villous morphology. This morphology may arise owing to aberrant molecular pathways such as BMP signaling, which controls villus-crypt homeostasis of gastrointestinal tract. Along with early events of *BRAF* or *KRAS* mutation, additional molecular changes drive proliferation of intestinal epithelium and shape them into TSA with distinct cytomorphology. Further accumulations of aberration in p53 and WNT signaling lead to progression of TSA into prominent dysplasia and CRC.

CONCLUSION
==========

TSAs are rare serrated polyps located predominantly in the distal colon. At least two pathways have been identified, converging on activation of MAPK by *BRAF* or *KRAS* mutations. Small HP/SSL-like lesions with *BRAF* mutations might initiate as TSA precursors. Whether it is the same case occurring in the small serrated lesion with *KRAS* mutation awaits further investigation. Because TSA-derived colorectal cancer is considered very aggressive\[[@B30]\], study of the TSA-carcinoma sequence, its progression from lack of dysplasia to high-grade atypia and malignancy, is also warranted in the future.
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